Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (EJNMMI Res., (2015), 5, (30), 10.1186/s13550-015-0103-5);Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer

EJNMMI Research

Volumn 5, Issue 1, 2015, Pages

  Saleem, Azeem ^a   Searle, Graham E ^a   Kenny, Laura M ^b   Huiban, Mickael ^a   Kozlowski, Kasia ^b   Waldman, Adam D ^b   Woodley, Laura ^a   Palmieri, Carlo ^c   Lowdell, Charles ^b   Kaneko, Tomomi ^d   Murphy, Philip S ^d   Lau, Mike R ^d   Aboagye, Eric O ^b   Coombes, Raoul C ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c Department of Molecular and Clinical Cancer Medicine ^*  (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Blood brain barrier; Her 2 positive breast cancer; Lapatinib bio distribution in brain metastases; PET imaging

Indexed keywords

CARBON 11; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD VOLUME; BRAIN METASTASIS; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84929018015     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-017-0323-y     Document Type: Erratum

References (16)

1. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–7.
2. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–43.
3. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49(5):650–5.
4. Polli JW, Humphreys JE, Harmon KA, Castellino S, O’Mara MJ, Olson KL, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008;36(4):695–701.
5. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.
6. Burris 3rd HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O’Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23(23):5305–13.
7. Gu H, Lu H, Ye FQ, Stein EA, Yang Y. Noninvasive quantification of cerebral blood volume in humans during functional activation. Neuroimage. 2006;30(2):377–87.
8. Taskar KS, Rudaraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29(3):770–81.
9. Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, Swanton C. Cancer: evolution within a lifetime. Annu Rev Genet. 2014;48:215–36.
10. Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, et al. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol. 2015;17(2):289–95.
11. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.
12. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.
13. Molina JR, Kaufmann SH, Reid JM, Rubin SD, Galvez-Peralta M, Friedman R, et al. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res. 2008;14(23):7900–8.
14. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos. 2009;37(2):439–42.
15. Leone F, Perissinotto E, Cavalloni G, Fonsato V, Bruno S, Surrenti N, et al. Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol. 2003;74(4):593–601.
16. Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015. Epub: 2015/01/22.